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The 5-HT6 receptor has emerged as a promising target for cognitive disorders and combining a 5-HT6
receptor antagonist with an acetylcholinesterase inhibitor (AChEI) represents a novel approach for the
symptomatic treatment of Alzheimer's disease (AD). A recent phase 2 trial showed that the selective 5-
HT6 receptor antagonist idalopirdine (Lu AE58054) improved cognition in patients with moderate AD on
stable treatment with the AChEI donepezil. Here we investigated the effects of idalopirdine in combi-
nation with donepezil on hippocampal function using in vivo electrophysiology and microdialysis.
Network oscillations in the hippocampus were recorded during electrical stimulation of the brainstem
nucleus pontis oralis (nPO) in the anesthetized rat and hippocampal acetylcholine (ACh) levels were
measured in the freely-moving rat. In addition, potential pharmacokinetic interactions between idalo-
pirdine and donepezil were assessed. Idalopirdine alone did not affect hippocampal network oscillations
or ACh levels. Donepezil (0.3 and 1.0 mg/kg i.v.) dose-dependently increased hippocampal theta and
gamma power during nPO stimulation. Idalopirdine (2 mg/kg i.v.), administered 1 h prior to donepezil,
potentiated the theta and gamma response to 0.3 mg/kg donepezil and prolonged the gamma response
to 1 mg/kg donepezil. Donepezil (1.3 mg/kg s.c.) increased extracellular ACh levels in the hippocampus
and this was further augmented by administration of idalopirdine (10 mg/kg p.o.) 2 h prior to donepezil.
These effects could not be attributed to a pharmacokinetic interaction between the compounds. This
study demonstrates that idalopirdine potentiates the effects of donepezil on two pharmacodynamic
biomarkers associated with cognition, i.e. neuronal oscillations and extracellular ACh levels in the hip-
pocampus. Such potentiation could contribute to the procognitive effects of idalopirdine observed in
donepezil-treated AD patients.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).an 6 receptor; 5-HT3a recep-
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Alzheimer's disease (AD) is themost common type of dementia
and the number of patients is expected to rise signiﬁcantly in the
coming decades due to the ageing worldwide population. Amyloid
plaques and neuroﬁbrillary tangles, caused by aberrant accumu-
lation of beta amyloid and tau proteins, respectively, result in
extensive neurodegeneration and are associated with the
dysfunction of several neurotransmitter systems. In particular the
hippocampus is affected early during the course of the disease. In
the absence of disease-modifying therapies, existing symptomatic
treatments aim to alleviate these deﬁcits in neurotransmission,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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in AD. Speciﬁcally, acetylcholinesterase inhibitors (AChEIs)
compensate for the deﬁcit in cholinergic signaling and the NMDA
receptor antagonist memantine modulates glutamatergic
signaling, both with a positive outcome on cognitive function.
However, due to the complexity and progressive nature of AD,
current symptomatic agents have proven inadequate and need to
be augmented with new therapies, especially at earlier stages of
the disease.
Another neurotransmitter system for which there is evidence
of dysfunction in AD is the serotonergic system (Arai et al., 1984;
Cross et al., 1983; Ichimiya et al., 1986) and serotonin is strongly
implicated in the regulation of learning and memory (Meneses,
2013; Leiser et al., 2015). The superfamily of serotonin (5-HT)
receptors consists of 7 subtypes. Of these, the 5-HT6 receptor,
which is positively coupled to the second messenger cyclic AMP
through the G-protein GaS, is among the latest identiﬁed mem-
bers (Monsma et al., 1993; Ruat et al., 1993). This receptor has
gained increasing attention as a putative target for the treatment
of cognitive disorders due to its presence in brain regions that
mediate learning and memory combined with its near exclusive
localization within the central nervous system (Hirst et al., 2003;
Helboe et al., 2015). Positron emission tomography (PET), ligand
binding and in-situ hybridization studies have demonstrated high
densities of the 5-HT6 receptor in the basal ganglia and moderate
densities in the hippocampus and cerebral cortex, both in humans
and rats (East et al., 2002; Roberts et al., 2002; Hirst et al., 2003;
Parker et al., 2012). In a recent study, we demonstrated that 5-
HT6 receptor mRNA is predominantly expressed in GABAergic
medium spiny neurons and in glutamatergic pyramidal cells, as
well as in subpopulations of GABAergic interneurons (Helboe
et al., 2015). This distinct localization allows the 5-HT6 receptor
to regulate the balance between inhibitory GABAergic and excit-
atory glutamatergic signaling and thus affect multiple transmitter
systems (reviewed in: Dawson, 2011). Pharmacological manipu-
lation in preclinical models has also provided compelling evi-
dence for the role of the 5-HT6 receptor in cognition and a number
of 5-HT6 receptor antagonists have reached clinical development
for cognitive disorders, most notably AD (Mitchell and Neumaier,
2005; Fone, 2008; Arnt et al., 2010; Meneses et al., 2011; Maher-
Edwards et al., 2011; Ramirez, 2013; Wilkinson et al., 2014). Of
these, idalopirdine (Lu AE58054), a high afﬁnity and selective
antagonist of the 5-HT6 receptor, is furthest advanced, and
currently in phase III development for the treatment of mild-
moderate AD.
Loss of cholinergic neurons is one of the pathological hallmarks
of AD. Innervation from the nucleus basalis of Meynert and the
medial septum to areas such as the cortex and hippocampus allows
the cholinergic pathway to inﬂuence multiple aspects of cognitive
function (Anand and Singh, 2013). Indeed, depletion of acetyl-
choline (ACh) and decreased cholinergic activity, predominantly in
the neocortex and hippocampus, are associated with cognitive
decline in AD (Davies and Maloney, 1976; Whitehouse et al., 1982).
Addressing this loss through AChEI treatment has beneﬁcial effects
on cognitive function in AD patients (Tsuno, 2009), although these
effects are consideredmodest (Birks and Harvey, 2006; Raina et al.,
2008; Tan et al., 2014). Interestingly, a number of preclinical
studies in rats have suggested that the neurochemical and pro-
cognitive effects of an AChEI can be potentiated by 5-HT6 receptor
antagonism (Marcos et al., 2008; de Bruin et al., 2011; Dawson,
2011). This concept is currently being pursued in clinical studies,
which suggest that combining a 5-HT6 receptor antagonist with an
AChEI provides a promising new approach for the symptomatic
treatment of AD (Maher-Edwards et al., 2011; Wilkinson et al.,
2014). Indeed, in a recent phase II trial, idalopirdine improvedthe cognitive performance of patients with moderate AD that were
on stable treatment with the AChEI donepezil (Wilkinson et al.,
2014).
Neuronal oscillations, as measured in the electroencephalogram
(EEG), represent synchronized activity of neuronal networks and
are essential for information processing (Draguhn et al., 2014). Of
these, theta (4e8 Hz) and gamma (30e48 Hz) oscillatory rhythms
are of particular interest as they have each been associated with
cognitive function (Bland, 1986; Colgin et al., 2009; Jutras et al.,
2009; Nyhus and Curran, 2010). In mild-moderate AD, oscillatory
changes most consistently described include a reduction of cortical
EEG power in the alpha and gamma bands and clinical studies have
shown a partial normalization of the oscillatory activity as a
consequence of AChEI treatment (reviewed by: Babiloni et al., 2013;
Basar et al., 2013). In the laboratory setting, theta and gamma os-
cillations in the hippocampus can be induced by high frequency
electrical stimulation of the brainstem nucleus pontis oralis (nPO)
in the anesthetized rodent (Vertes, 1982; Kinney et al., 1999). This
activates an ascending pathway from the brainstem to the septum/
diagonal band of Broca, providing the hippocampus with cholin-
ergic, glutamatergic and GABAergic input (Vertes, 1981; Bland and
Oddie, 1998; Stoiljkovic et al., 2015). In addition, serotonergic
modulation of the hippocampal theta rhythm during brainstem
stimulation has been demonstrated with several serotonin receptor
ligands (Sorman et al., 2011; Johnson et al., 2012; Zhu and
McNaughton, 1994). These studies are performed under anes-
thesia which prevents the confounding effects of movement on
oscillatory activity and inhibits spontaneous theta oscillations
(Buzsaki, 2002). Donepezil and several pharmacological agents that
enhance cognition, were shown to increase the power and peak
frequency of hippocampal theta oscillations during stimulation of
the nPO (McNaughton et al., 2007; Kinney et al., 1999) suggesting
that this assay is suitable to investigate the effects of procognitive
compounds on hippocampal network activity relevant for
cognition.
The present study further investigates the underlying mecha-
nisms by which 5-HT6 receptor antagonismmay improve cognition
and provide added beneﬁt when combined with AChEIs. For this
purpose, we examined the effects of idalopirdine alone and in
combination with donepezil on hippocampal oscillations during
stimulation of the nPO in the anesthetized rat and on extracellular
levels of ACh in the hippocampus of the awake and freely moving
rat. In addition, we examined the potential pharmacokinetic in-
teractions between idalopirdine and donepezil.
2. Methods
2.1. Animals
Animal studies were carried out in accordance with the Euro-
pean Communities Council Directive (86/609/EEC) for the care and
use of laboratory animals and the Danish legislation regulating
animal experiments. Male Sprague Dawley rats (Charles River,
Germany) were housed in pairs under controlled temperature
(22 ± 1.5 C) and humidity conditions (55e65%) and kept on a
12:12 h light/dark cycle (lights on at 06:00). Food and water was
available ad libitum.
2.2. Drugs
For electrophysiological studies, donepezil (Medicinal chemis-
try, H. Lundbeck A/S) was dissolved in 0.9% saline and administered
intravenously (i.v.) at doses of 0.3 and 1 mg/kg in a volume of 1 ml/
kg. Idalopirdine was dissolved in isotonic 5% glucose and admin-
istered i.v. at doses of 1 and 2 mg/kg in a volume of 1 ml/kg. 5%
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For microdialysis studies, idalopirdine was dissolved in 5% 2-
hydroxypropylbeta-cyclodextrin (Hp-beta-CD) and administered
orally (p.o.) at doses of 1, 5 or 10 mg/kg in a volume of 5 ml/kg.
Donepezil was dissolved in 5% Hp-beta-CD and administered sub-
cutaneously (s.c.) at a dose of 1.3 mg/kg in a volume of 2.5 ml/kg 5%
Hp-beta-CD was used as vehicle. All doses are expressed as mg free
base/kg body weight.
2.3. Electrophysiology
2.3.1. Surgery
Experiments were performed in rats weighing 250e450 g,
anesthetized with an intraperitoneal injection of 1.5 g/kg urethane
(supplemented if needed to reduce spontaneously occurring theta
oscillations). Each animal was surgically implanted with a femoral
catheter (P50 tubing) for i.v. administration of compounds. Animals
were placed in a stereotaxic frame (Kopf, Tugunga, CA, USA) and the
body temperature was monitored by rectal probe and maintained
at 37 C via a homeothermic blanket. The skull directly over the
bregma-lambda suture was exposed followed by burring a small
hole in the right frontal bone for placement of a silver grounding
electrode. Additional holes were burred into the left parietal bone
for placement of the recording electrode in the hippocampal ﬁssure
(coordinates relative to bregma in mm (Paxinos and Watson 1986:
AP (anterior posterior)3.5mm, L (lateral) 2.0e2.2 mm, V (ventral)
2.9e3.1 mm) and the stimulating electrode in the nPO (AP 8.0 mm;
L 1.6 mm; V 6mm). Following surgery, the animals were kept in the
stereotaxic frame for the duration of the experiment and allowed to
stabilize for 1e2 h prior to beginning each recording.
2.3.2. Recording and stimulation
Field potentials (EEG activity) were recorded using unipolar
stainless steel electrodes (0.005/0.125 mm, Plastics One, Roanoke,
VA) and a Grass model P55 AC ampliﬁer (Grass Instruments, West
Warrick, RI) with the ﬁlters set at 0.1 and 100 Hz (high pass/low
pass respectively) and the 50 Hz notch ﬁlter in the off position. The
signals were digitized at a rate of 1 kHz (CED Micro 1401, Cam-
bridge Electronic Design, Ltd, Cambridge, UK) and stored on a PC for
subsequent off-line analysis using Spike2 software (version 7.10,
Cambridge Electronic Design). The nPOwas stimulated via a bipolar
concentric 400 mm tungsten electrode (TM53CCINS, World Preci-
sion Instruments, Inc., USA). Hippocampal oscillations were
induced every 100 s by application of a 6 s train of 0.3 ms square
pulses at 250 Hz controlled via the Spike2 software and a A365
stimulus isolator (World Precision Instruments, Inc., USA). The
depth of the recording electrode was adjusted in order to yield high
amplitude theta power, which was typically obtained at the level of
the hippocampal ﬁssure as described previously (Kowalczyk and
Konopacki, 2002). The stimulation intensity was adjusted so that
the peak frequency of the evoked signal was between 5 and 6 Hz,
and typically ranged from 100 to 150 mA in amplitude. After a stable
baseline was established (>1 h), vehicle or idalopirdine was
administered and EEG was recorded for a further 1 h before a
second dose of vehicle or donepezil was injected. Only studies
where a stable baseline was established before drug injection were
used in the data analysis. At the end of each experiment a 200 mA
current was applied through the electrodes, rats were euthanized
with a bolus injection of urethane and brains were removed for
veriﬁcation of electrode placement. Only experiments in which
electrodes were correctly placed were included in the data analysis.
2.3.3. Data analysis
The signal processing of local ﬁeld potential (LFP) activity was
computed inMATLAB, using functions implemented in the Fieldtriptoolbox (http://www.ru.nl/fcdonders/ﬁeldtrip/) and the sigTOOL
toolbox (http://sigtool.sourceforge.net/sigtool.html).
2.3.3.1. Pre-processing. Epochs with high amplitude electrical noise
were visually identiﬁed andmanually removed before data analysis
in Spike2. The recordings were imported in MATLAB and
segmented into epochs extending from 5 s before nPO stimulation
to 5 s after nPO stimulation. The epochs were baseline corrected, to
remove any standing offset, by subtracting the average amplitude
in the pre-nPO period from the entire epoch. Artefact correction
was then performed for each recording, based on the standard
score (zEEG,t) of each sample:
zEEG;t ¼




xEEG;t  mEEG
sEEG




Any sample with an extreme value, i.e. 18 standard scores from
the mean, was considered an artefact. The artefacts were excluded
from analysis.
2.3.3.2. Spectral analysis and statistics. To investigate the effect of
nPO stimulation itself and the impact of the treatments, power
spectra were computed using a fast Fourier transform between 1
and 50 Hz with a Hamming window on 5 s epochs downsampled to
500 Hz. Where relevant, frequency bands were compared by paired
t-test or Wilcoxon signed rank test. Further investigation of a
treatment effect was completed by performing a short-time Fourier
transform using a ﬁxed 1 s Gaussian window on each epoch in the
frequency interval 1e48 Hz. The treatment response over time was
computed using the average raw power over time before and
during each stimulation (epoch); pre-nPO (5e0 s) and during nPO
(the last 5 s of the 6 s nPO-period were used). To visualize a power
change from baseline, the power was normalized to the average
baseline power in each frequency bin. Subsequently, oscillatory
activity was divided into the 5 main frequency bands: delta; 04 Hz,
theta; 48 Hz, alpha; 813 Hz, beta 1330 Hz: gamma; 3048 Hz and
compared between treatments. The data are expressed as group
mean ± SEM. Data were analyzed by two-way repeated measures
ANOVA with treatment as between-subject factor and time (35
stimulation epochs) as within-subject factor, followed by a Holm
Sidak post hoc analysis, using SigmaPlot (version 11.0).
2.4. Microdialysis
2.4.1. Surgery
Rats weighing 275e300 g were anesthetized with hypnorm/
dormicum (2 ml/kg) and intracerebral guide cannulas (CMA/12)
were stereotaxically implanted into the brain, aiming to position
the dialysis probe tip in the dorsal hippocampus (coordinates: AP -
4.3 mm, L - 2.6 mm, V - 4.0 mm) according to Paxinos and Watson
(Paxinos and Watson, 1986). Anchor screws and acrylic cement
were used for ﬁxation of the guide cannulas. The body temperature
of the animals was monitored by rectal probe and maintained at
37 C via a homeothermic blanket. The rats were allowed to recover
from surgery for 2 days, single-housed.
2.4.2. Microdialysis experiments
On the day of the experiment a microdialysis probe (CMA/12,
0.5 mm diameter, 2 mm length) was inserted through the guide
cannula. The probes were connected via a dual channel swivel to a
microinjection pump. Perfusion of the microdialysis probe with
ﬁltered Ringer solution (145 mm NaCl, 3 mM KCl, 1 mM MgCl2,
1.2 mM CaCl2) was begun shortly before insertion of the probe into
the brain and continued for the duration of the experiment at a
constant ﬂow rate of 1 ml/min. After 180 min of stabilization, the
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After the experiments the animals were euthanized and the brains
were removed for veriﬁcation of probe placement. Only those an-
imals with correct placement were included in the data analysis.
2.4.3. Analysis of ACh in rat brain microdialysate
ACh concentrations in microdialysis samples were determined
by means of ultra-performance liquid chromatography (UPLC)
coupled to tandem mass spectrometry (MS/MS) without any sam-
ple preparation. A standard curve was prepared in Ringer's solu-
tions containing ACh concentrations in the range of 0.01e10 ng/ml.
2 ml of sample or standard, refrigerated to 10 C in the autosampler,
was injected onto the chromatographic system (Waters Aquity
UPLC, Milford, MA) equipped with a Primesep 200 column
(2,1  50 mm, 3 mM particles, 100 A pore size; SIELC Technologies,
Wheeling, IL) operated at room temperature at a ﬂow rate of 0.6ml/
min. The mobile phase consisted of 0.1% formic acid in water and
acetonitrile pumped through the column as a gradient resulting in a
retention time of 0.95 min. ACh was detected in positive-ion elec-
trospray ionization MS mode with parent/daughter transition of
146.2/87.1 using a Waters TQ-S system (Milford, MA). The total
runtime was 5 min for each sample. The limit of quantitation was
0.01 ng/ml (signal-to-noise ratio >6). Data acquisition and analysis
was performed using Masslynx software, version 4.1 (Waters,
Milford, MA).
2.4.4. Data analysis and statistics
In the data analysis the mean value of 3 consecutive ACh sam-
ples immediately preceding donepezil/vehicle administration
served as the basal level for each experiment and data were con-
verted to percentage of basal (mean basal pre-injection values
normalized to 100%). The data are expressed as group mean ± SEM.
Data were analyzed by two-way repeated measures ANOVA fol-
lowed by a Student-Newman Keuls post hoc analysis using Sig-
maPlot (version 11.0).
2.5. Plasma and brain exposure of idalopirdine and donepezil
2.5.1. Exposure studies
Plasma and brain concentrations of donepezil and idalopirdine
were investigated in separate groups of rats. In parallel to the
electrophysiology studies, rats were dosed with idalopirdine (1 or
2 mg/kg i.v.) or vehicle 1 h prior to donepezil (0.3 or 1 mg/kg i.v.) or
vehicle. Blood samples were collected in EDTA coated tubes at t¼ 0,
5, 15, 30 and 60 min and brain tissue at t ¼ 60 min after donepezil
administration, corresponding to t ¼ 60, 65, 75, 90 and 120 min
after idalopirdine administration. In parallel to the microdialysis
study, idalopirdine (10mg/kg p.o.) or vehicle were administered 2 h
prior to donepezil (1.3 mg/kg s.c.) or vehicle. Blood samples were
collected at t ¼ 30 and 60 min and brain tissue at t ¼ 60 min after
donepezil administration, corresponding to t ¼ 150 and 180 min
after idalopirdine administration. Blood samples were centrifuged
for 10 min at 5000 g at 4 C, and plasma was stored together with
the brain samples at 80 C until sample preparation and
bioanalysis.
2.5.2. Quantitative bioanalysis
Rat plasma and brain concentrations of idalopirdine and done-
pezil were determined using UPLC-MS/MS. Brain homogenate
samples were prepared by homogenizing the whole brainwith 70%
acetonitrile (1:4, v/v) followed by centrifugation and collection of
the supernatant. Plasma or brain samples (25 ml) were precipitated
with 150 ml acetonitrile containing internal standard. For idalo-
pirdine, a 13C-labelled internal standard was used. After centrifu-
gation, 100 ml supernatant from each sample was transferred to anew plate and mixed with 100 ml 0.1% formic acid. After a quick
centrifugation the samples were placed in the autosampler. Chro-
matography was performed on a Waters Aqurity C18 SB HSS col-
umn (30  2.1 mm, 1.8 mm particles) using a mobile phase gradient
of 0.1% formic acid in water and acetonitrile pumped through the
columnwith a ﬂow rate of 0.6 ml/min. The retention time was 1.13
and 0.93 min for idalopirdine and donepezil, respectively. MS/MS
detection was done with an Applied Biosystems Sciex API 4000
instrument in positive-ion electrospray ionization mode (AB Sciex,
Foster City, CA). Mass to charge ratios (m/z) of 399.1 > 221.1 and
380.2 > 91.2 were used for detection of idalopirdine and donepezil,
respectively. Nitrogen was used for the nebulizer and collision
gases. The peak area correlated linearly with the concentration in
the range of 0.5e1000 ng/ml in plasma and 2.5e5000 ng/g in brain
for both analytes. Data acquisition and analysis was performed
using Analyst software, version 6.1 (AB Sciex, Foster City, CA).
2.5.3. Data analysis and statistics
Plasma concentrations of idalopirdine and donepezil in ng/ml
are depicted over time. Themean areas under the curve (AUC) were
calculated and compared by one-way ANOVA or student's t-test, as
appropriate. At the terminal time point brain concentrations of
idalopirdine and donepezil in ng/g were compared by one-way
ANOVA or student's t-test, followed by a Bonferroni post-hoc
analysis.
3. Results
3.1. Local ﬁeld potential oscillations in the dorsal hippocampus of
the anesthetized rat
3.1.1. Effect of electrical stimulation of nPO on local ﬁeld potential
oscillations in the hippocampus
During baseline recording, delta oscillations (<4 Hz) were
prominent whilst theta oscillations were limited in the CA1 area of
the hippocampus, with no clear peak in the 4e8 Hz theta band. As
previously reported (Vertes, 2005; Kinney et al., 1999; Siok et al.,
2009, 2012), electrical stimulation of the nPO resulted in highly
regular and robust hippocampal CA1 theta oscillations in the EEG
(Fig. 1A1 and B). nPO stimulation resulted in a peak theta frequency
of 5.0 ± 0.07 Hz (n ¼ 44) and an overall 4.5 fold increase in theta
power (Wilcoxon singed rank test, p < 0.001). In contrast, gamma
oscillations (30e48 Hz) were not signiﬁcantly increased by nPO
stimulation per se (paired student's t-test: P ¼ 0.614, Fig. 1A). The
theta power during nPO stimulation could be further augmented by
administration of donepezil alone or in combination with idalo-
pirdine, whereas gamma power was only enhanced during nPO
stimulation by treatment with the combination of idalopirdine and
donepezil, as exempliﬁed by Fig. 1B. There were no treatment ef-
fects on gamma power above 50 Hz (data now shown). Since in-
jection of vehicle did not signiﬁcantly alter responses to nPO
stimulation (theta: paired student's t-test: P ¼ 0.251, Fig. 1 A2),
compound effects were normalized to the 30 min baseline directly
before compound administration in the following analyses.
3.1.2. Effect of idalopirdine and donepezil on theta and gamma
during nPO stimulation
There were no treatment effects on spontaneous oscillations
(Fig. 2, left panel), therefore compound effects are described during
nPO stimulation (Fig. 2, right panel and Fig. 3). Idalopirdine (1 or
2 mg/kg i.v.) alone did not have a signiﬁcant effect on theta or
gamma oscillations during nPO stimulation in the 60 min period
prior to donepezil administration (Figs. 2 and 3). We have previ-
ously observed that, in this time window, idalopirdine concentra-
tions in the brain correspond to high receptor occupancy (data not
Fig. 1. Effect of electrical stimulation of the nPO alone and in combination with treatment on hippocampal oscillations. (A) Powerspectra of hippocampal local ﬁeld po-
tentials. (A1) Average power spectra before (red) and during (blue) nPO stimulation. (A2) Average power spectra before (blue) and following (green) vehicle administration during
nPO stimulation. (B) Representation of compound effects on nPO stimulated hippocampal oscillations. Red horizontal brackets indicate nPO stimulation periods (time 0e6 s). Blue
waveforms in the top panels depict average LFPs from one animal each (average of 6 stimulations taken from 5 to 15 min after last compound injection). Heatplots in the bottom
panels show grand average power spectrograms (6 stimulations, 5e15 min after last compound injection) of each treatment group: vehicleevehicle (B1, n ¼ 7), vehiclee0.3 mg/kg
donepezil (B2, n ¼ 7) and idalopirdine 2.0 mg/kgedonepezil 0.3 mg/kg (B3, n ¼ 7), normalized to baseline; 5e0 s relative to stimulus onset.
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increased theta and gamma power when compared to vehicle
treatment (theta: F[treatment]2,553 ¼ 3.569, P ¼ 0.049 and gamma:
F[treatment]2,553 ¼ 5.386, P ¼ 0.015, Figs. 2 and 3), without shifting
peak-frequencies (data not shown). Donepezil 1 mg/kg increased
theta power compared to 0.3 mg/kg donepezil (P < 0.05) at the
peak effect, 6e7 min after administration, and compared to vehicle
treatment (P < 0.05) extending to 12 min after administration.
Similarly, donepezil 1 mg/kg increased gamma power compared to
0.3 mg/kg donepezil (P < 0.05) from 610 min after administration
and compared to vehicle treatment (P < 0.05) up to 25 min after
administration. There was no signiﬁcant effect of donepezil 0.3 mg/
kg on either theta (P ¼ 0.691) or gamma power (P ¼ 0.059),
although there was a trend towards an increase in gamma power
(150%).3.1.3. Effect of idalopirdine in combination with donepezil on
hippocampal theta during nPO stimulation
Idalopirdine 2.0 mg/kg in combination with donepezil 0.3 mg/
kg signiﬁcantly augmented theta power during nPO stimulation as
compared to vehicle treatment (P < 0.05), while there was no sig-
niﬁcant effect of donepezil 0.3 mg/kg alone (F
[treatment]3,790 ¼ 1.334, P ¼ 0.287, F[time]34,790 ¼ 7.595, P < 0.001,
F[treatment  time]102,790 ¼ 3.792, P < 0.001, Fig. 3A, top panel and
supplementary Fig. 1A, top panel). This effect persisted until 15 min
after injection. Plasma concentrations of donepezil were similar in
the presence and absence of idalopirdine in this time window,
indicating that this was not caused by a PK interaction (Fig. 5A). In
contrast, the lower dose of 1.0 mg/kg idalopirdine did not modify
the response to donepezil 0.3 mg/kg on theta power (Fig. 3A, top
panel and supplementary Fig. 1A, top panel).
Fig. 2. Effect of idalopirdine, donepezil and the combination before and during nPO stimulation on the spectral power of hippocampal oscillations. Effects of the treatments
on hippocampal oscillations (Hz) as a function of time; prior to nPO stimulation (left column) and during nPO stimulation (right column). nPO stimulations were repeated every
100 s and each vertical time bin in a heatplot represents the average spectral power of one such epoch, either pre-nPO (5e0 s) or during nPO (1e6 s). Idalopirdine (IDL) or vehicle
(veh) were administered at time 0, donepezil (DPZ) or veh at time 60. Heatplots show the average spectral power of each treatment group (n ¼ 7e9) standardized to the baseline
period before drug or vehicle administration (30e0 min relative to 1st injection).
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of the higher dose of 1.0 mg/kg donepezil on elicited theta power (F
[treatment]2,652 ¼ 3.334, P¼ 0.056, F[time]34,652 ¼ 2.325, P < 0.001,
F[treatment  time]68,652 ¼ 1.118, P ¼ 0.249, Fig. 3B, top panel),
although the combination of idalopirdine 2.0 mg/kg and donepezil
1.0 mg/kg did elevate theta power as compared to vehicle treat-
ment during the peak response (5e15 min after donepezil admin-
istration, Fig. 3B, top panel and supplementary Fig. 1B, top panel).
3.1.4. Effect of idalopirdine in combination with donepezil on
hippocampal gamma during nPO stimulation
Idalopirdine 2.0 mg/kg in combination with donepezil 0.3 mg/
kg signiﬁcantly increased gamma power during nPO stimulation as
compared to vehicle treatment (P < 0.05), while there was no sig-
niﬁcant effect of donepezil 0.3 mg/kg alone (F
[treatment]3,790 ¼ 3.321, P ¼ 0.037, F[time]34,790 ¼ 6.251, P < 0.001,
F[treatment  time]102,790 ¼ 1.173, P ¼ 0.129, Fig. 3A, bottom paneland supplementary Fig. 1A, bottom panel). This effect persisted for
the duration of the experiment. Plasma concentrations of donepezil
were similar in the presence and absence of idalopirdine in this
time window, indicating that this was not caused by a PK interac-
tion (Fig. 5A). In contrast, the lower dose of 1.0 mg/kg idalopirdine
did not modify the response to donepezil 0.3 mg/kg on gamma
power (Fig. 3A, bottom panel and supplementary Fig. 1A, bottom
panel).
The combination treatment of idalopirdine 2 mg/kg and the
higher dose of 1.0 mg/kg donepezil increased gamma power during
nPO stimulation as compared to vehicle treatment (P < 0.01) and
donepezil 1.0 mg/kg alone (P < 0.05) (F[treatment]2,652 ¼ 9.337,
P ¼ 0.001, F[time]34,652 ¼ 6.049, P < 0.001, F
[treatment  time]68,652 ¼ 1.666, P ¼ 0.001, Fig. 3B, bottom panel
and supplementary Fig. 1B, bottom panel). Idalopirdine 2 mg/kg
prolonged the effects of donepezil 1 mg/kg on gamma power for
the duration of the treatment period without changing the peak-
Fig. 3. Effect of idalopirdine, donepezil and the combination on theta and gamma power during nPO stimulation in the hippocampus. Effects of the treatments on hip-
pocampal theta (4e8 Hz) and gamma (30e48 Hz) power. Idalopirdine (IDL) or vehicle (veh) were administered at time 0, donepezil (DPZ) or veh at time 60. Column A depicts
donepezil at the low dose (0.3 mg/kg) in combination with idalopirdine (1 or 2 mg/kg), column B donepezil at the high dose (1.0 mg/kg) in combination with idalopirdine (2 mg/kg).
The top row depicts theta power, the bottom row gamma power. Data are presented as mean power relative to the 30 min baseline ± SEM. *P < 0.05 IDL/DPZ vs. veh/veh, #P < 0.05
veh/DPZ vs. veh/veh, yP < 0.05 IDL/DPZ vs. veh/DPZ. N ¼ 7e9.
K.F. Herrik et al. / Neuropharmacology 107 (2016) 351e363 357effect. There was a transient increase in exposure of donepezil
1.0 mg/kg in combinationwith idalopirdine 2mg/kg during the ﬁrst
5 min after donepezil administration (Fig. 5B), however this is
unlikely to explain the lasting effect of the combination treatment
on gamma power.3.2. Extracellular levels of ACh
Rats were pretreated with idalopirdine (p.o.) 2 h before
administration of donepezil/vehicle (s.c.). The absolute basal levels
of extracellular levels of ACh in the dorsal hippocampus without
considering probe recovery were 0.05 ± 0.005 (n ¼ 28) and
0.05 ± 0.004 (n ¼ 26) ng/mL dialysate in animals pretreated with
vehicle and idalopirdine (10 mg/kg), respectively. Thus, idalo-
pirdine administered alone did not affect hippocampal ACh levels.
Administration of donepezil and donepezil in combination with
idalopirdine increased the extracellular levels of hippocampal ACh
(F[treatment]2,84¼15.712, P < 0.001, Fig. 4A). Injection of donepezil
at 1.3 mg/kg increased hippocampal ACh levels by approximately
900% (P ¼ 0.089, Fig. 4A). Administration of idalopirdine (10 mg/kg
p.o.) 2 h prior to injection of donepezil signiﬁcantly enhanced the
donepezil-induced increases in ACh levels (P ¼ 0.006, Fig. 4A). In a
separate study administration of idalopirdine at 10 mg/kg p.o., but
not 1 or 5 mg/kg, potentiated the donepezil-induced increase in
levels of ACh (F[treatment]4,213 ¼ 20.599, P < 0.001, Fig. 4B).
Donepezil alone signiﬁcantly (P < 0.001) increased the levels of ACh
and pretreatment with idalopirdine at 10 mg/kg signiﬁcantly
augmented this increase in ACh levels (P < 0.001). Similarly, we
have observed a potentiation when idalopirdine (10 mg/kg p.o.)
was combined with a lower dose of donepezil (0.5 mg/kg, s.c.) (datanot shown, F[treatment]2,79 ¼ 5.675, P ¼ 0.015). In a parallel study,
there was shown a pharmacokinetic (PK) interaction between the
compounds when idalopirdine was administered 2 h prior to in-
jection of donepezil (1.3 mg/kg s.c.). An approximate 30% increase
in donepezil plasma and brain exposure was observed in animals
pretreated with idalopirdine (Fig. 7A and C). We therefore inves-
tigated the potential impact of the 30% increase in donepezil
exposure on extracellular levels of ACh in a separate study. An
attempt to mimic an increase of approximately 30% was made by
injecting donepezil at 1.3 and 1.7mg/kg (s.c.). Despite an increase in
brain exposure of donepezil of approximately 60% after adminis-
tration of 1.7 mg/kg, the detected increase in hippocampal ACh
levels was not signiﬁcant compared with the levels induced by
1.3 mg/kg donepezil (Supplementary Fig. 2).3.3. Exposure of idalopirdine and donepezil following i.v.
administration
Plasma and brain concentrations of idalopirdine and donepezil
were determined in a separate group of rats parallel to the elec-
trophysiology studies (Figs. 6 and 7). Donepezil plasma concen-
trations increased dose-dependently and pretreatment with
idalopirdine (1 or 2 mg/kg, i.v.) did not modulate plasma AUC of
donepezil dosed at 0.3 mg/kg, i.v. (Fig. 5A, F[AUC]2,11 ¼ 2.927,
P ¼ 0.1049) or at 1 mg/kg, i.v. (Fig. 5B, t[AUC] ¼ 0.6881, P ¼ 0.5171),
although in the latter paradigm, a transient increase in donepezil
concentration was observed during only the ﬁrst 5 min after
donepezil administration in rats pretreated with idalopirdine
(t ¼ 3.103, P < 0.05). This did not translate to an increase in brain
exposure as brain concentrations of donepezil increased dose-
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(Fig. 6A, F4,19 ¼ 43.98, P < 0.0001. P < 0.05 donepezil 1.0 vs. done-
pezil 0.3, irrespective of pretreatment, Bonferroni post hoc). Plasma
concentrations of idalopirdine increased dose-dependently and the
plasma AUC of idalopirdine 2 mg/kg was not modulated by
administration of donepezil 0.3 or 1 mg/kg (Fig. 5D, F
[AUC]2,11 ¼ 1.193, P ¼ 0.3472). When idalopirdine 1 mg/kg was
followed by donepezil 0.3 mg/kg, a marginal elevation in idalo-
pirdine plasma concentrations was observed (Fig. 5C, t
[AUC] ¼ 2.807, P < 0.05). However, this did not translate to an in-
crease in brain exposure as brain concentrations of idalopirdine
increased dose-dependently without being affected by donepezil
treatment (Fig. 6B, F4,19 ¼ 13.32, P < 0.0001. P < 0.05 idalopirdine 2vs. 1 mg/kg, irrespective of donepezil treatment, Bonferroni post
hoc).
3.4. Exposure of idalopirdine and donepezil following p.o. and s.c.
administration, respectively
Plasma and brain concentrations of idalopirdine 10 mg/kg p.o.
and donepezil 1.3 mg/kg s.c. were determined in a separate group
of rats parallel to the microdialysis study. Pretreatment with ida-
lopirdine increased plasma and brain concentrations of donepezil
by approximately 30% (plasma: Fig. 7A, t[AUC] ¼ 2.341, P < 0.05,
brain: Fig. 7C, t ¼ 2.897, P < 0.05). In contrast, plasma and brain
concentrations of idalopirdine were not modulated by donepezil
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K.F. Herrik et al. / Neuropharmacology 107 (2016) 351e363 359administration (plasma: Fig. 7B, t[AUC] ¼ 0.140, P ¼ 0.890, brain:
Fig. 7D, t ¼ 1.522, P ¼ 0.162). When comparing the two adminis-
tration paradigms for the nPO and microdialysis assays (Figs. 5e7),
it is noteworthy that the plasma and brain concentrations of
donepezil following i.v. (0.3e1.0 mg/kg) and s.c. (1.3 mg/kg)
administration were in a comparable range, whereas idalopirdine
exposure obtained in the p.o. (10 mg/kg) paradigm was 2e5 fold
higher (brain and plasma, respectively) than in the i.v. (2 mg/kg)
paradigm.4. Discussion
In the present study we demonstrate that the 5-HT6 receptor
antagonist idalopirdine potentiates the effects of donepezil on
neuronal oscillations and extracellular levels of ACh in the hippo-
campus of the rat, two pharmacodynamic biomarkers that are
associated with cognitive function.
In the current studies, donepezil had no impact on spontane-
ously occurring oscillatory activity in the urethane-anesthetized rat
but did signiﬁcantly increase theta and gamma power during nPO
stimulation without signiﬁcantly shifting the peak frequencies.
Similarly, it has previously been shown that donepezil enhanceshippocampal theta and gamma power during nPO stimulation in
the anesthetized rat (Kinney et al., 1999; McNaughton et al., 2007)
and both spontaneous theta and gamma power in the awake freely
moving rat (Ahnaou et al., 2014). The effect of i.v. donepezil on theta
and gamma oscillatory activity was dose-dependent up to 1 mg/kg.
In pilot experiments, we did not observe further increases with 2 or
3 mg/kg doses of donepezil during nPO stimulation (unpublished
data), which led us to conclude that there was an upper limit to the
effects of donepezil on hippocampal theta and gamma power. This
is in agreement with two other studies demonstrating a ceiling to
the effects of donepezil on hippocampal oscillations in the nPO
stimulation assay and in a slice preparation (Kinney et al., 1999;
Spencer et al., 2010). It should be noted that, in the Kinney study,
the effective dose-range of donepezil in the nPO assay was
considerably higher than in the current study (0.1e10 mg/kg, with
an apparent ceiling at 3 mg/kg) and that the duration of the
donepezil effect was longer, both of which are likely explained by
the different routes of donepezil administration between the
studies (i.p. vs. i.v.).
Here we show that the effects of donepezil can be further
potentiated by 5-HT6 receptor antagonism. Idalopirdine (2 mg/kg
i.v.), while not having an effect alone, markedly increased theta and
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donepezil. At this dose of donepezil, plasma concentrations were
within the range of clinically relevant concentrations (25e50 ng/
ml) (Rogers et al., 1998; Tiseo et al., 1998) which were not changed
by co-dosing of idalopirdine. Furthermore, idalopirdine (2 mg/kg)
signiﬁcantly prolonged the effect of donepezil 1 mg/kg on gamma
power in the time frame where donepezil exposure was not
affected by idalopirdine pretreatment. Therefore, we conclude that
idalopirdine potentiates and/or prolongs the effects of donepezil on
neuronal oscillations in the hippocampus, at a dose of donepezil
that correlates to clinically relevant plasma concentrations, which
cannot be attributed to a pharmacokinetic interaction between the
compounds. This effect was only observed with the higher dose of
idalopirdine (2 mg/kg) where plasma concentrations reached
approximately 90 ng/ml, which is above previously reported
plasma concentration of 20 ng/ml leading to 50% occupancy of the
5-HT6 receptor in vivo in rats (Arnt et al., 2010).
In continuation of this, it will be of great interest to study how
idalopirdine alone, and in combination with donepezil, affects
oscillatory activity in the awake rat during performance of a
cognitive task. Few studies have addressed the effects of 5-HT6 li-
gands on EEG in awake animals. Ly et al. found no effect of the 5-
HT6 receptor antagonist SAM-531 in either awake or anesthetized
rats, in line with the present ﬁndings, whereas the 5-HT6 agonist
EMD386088 was shown to decrease theta peak frequency and
suppress sleep (Ly et al., 2013).
In the freely moving rat, we demonstrated that idalopirdine
enhanced donepezil-induced increases in extracellular levels of
hippocampal ACh. This effect was dose-dependent since only the
highest dose (10 mg/kg p.o.) of idalopirdine tested induced a sig-
niﬁcant increase in ACh, indicating that a high 5-HT6 receptor oc-
cupancy (>70%) is required (Arnt et al., 2010). A small PKinteraction was observed with the dosing regimen used for the
microdialysis study, as donepezil brain exposure increased by
approximately 30% in the presence of idalopirdine. When
mimicking this increase in brain exposure of donepezil by injecting
a higher corresponding dose of donepezil, the observed increase in
ACh levels was not signiﬁcant. Thus, it was concluded that the
signiﬁcant increase in ACh levels induced by idalopirdine cannot be
explained solely by a pharmacokinetic interaction between the
compounds. Consistent with the data from the present study, a
similar observation was reported by Dawson showing that the 5-
HT6 receptor antagonist SB-742457 alone exerted a minimal ef-
fect on cortical ACh levels, but enhanced the effect of donepezil on
ACh levels (Dawson, 2011). Positive effects of 5-HT6 receptor
antagonism have also been observed in two other microdialysis
studies, which demonstrated that systemic treatment with 4-(2-
bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine (Riemer
et al., 2003) and SB-399885 (Hirst et al., 2006) increased ACh
levels in the rat brain. However, in these two studies an AChEI was
included in the microdialysis perfusion solution to increase the
extracellular ACh levels to detectable levels. Thus, these studies
may rather have demonstrated that a 5-HT6 receptor antagonist
potentiates the effect of an AChEI on ACh levels.
The effects of 5-HT6 receptor antagonists on extracellular ACh
are most likely indirect, as there is no evidence for the presence of
5-HT6 receptors on cholinergic neurons (Marcos et al., 2006;
Helboe et al., 2015). Therefore, the effect of 5-HT6 receptor antag-
onism will depend not only on serotonergic tone, but also on the
dynamics of other systems, particularly GABA and glutamate, in
linewith the localization of the 5-HT6 receptor (Helboe et al., 2015).
Indeed, it has been demonstrated that a 5-HT6 receptor agonist
enhances extracellular GABA levels both after acute and subchronic
treatment (Schechter et al., 2008). We have also demonstrated that
acute administration of the 5-HT6 receptor agonist WAY-181187
increases extracellular GABA levels in the cortex, an effect which
was blocked by idalopirdine (Herrik et al., 2013). Conversely, WAY-
181187 was found to reduce stimulated glutamate release in a
hippocampal slice preparation (Schechter et al., 2008) whereas two
5-HT6 receptor antagonists have been reported to increase extra-
cellular levels of glutamate (Dawson et al., 2001; Chuang et al.,
2006). Thus, local enhancement of cholinergic function by 5-HT6
receptor antagonism may depend on inhibition of GABAergic and/
or facilitation of glutamatergic signaling in relevant brain areas.
The observation that 5-HT6 receptor antagonists primarily
enhance the effect of donepezil on ACh levels and hippocampal
oscillatory activity, rather than being efﬁcacious on their own, may
suggest that the effect of 5-HT6 receptor antagonism requires a
certain cholinergic tone provided by the AChEI (current study;
Dawson, 2011). However, idalopirdine monotherapy fully reversed
a cognitive deﬁcit induced by subchronic phencyclidine treatment
in the rat novel object recognition test (Arnt et al., 2010). Moreover,
we have recently observed that, in the prefrontal cortex of the rat,
idalopirdine (2 mg/kg i.v.) increases nPO stimulation-induced
gamma oscillations as monotherapy as well as adjunctive therapy
to donepezil (Foraster et al., 2014). This leads us to speculate that
the effect of 5-HT6 antagonists depends on the context (e.g. brain
region, behavioral task or disease state), which may differ in sero-
tonergic tone, as well as to the degree in which other neurotrans-
mitter systems are engaged. In addition, it will be of interest to
study whether idalopirdine can also act through inverse agonism
and achieve some of its neuropharmacological effects independent
of the endogenous serotonergic tone, which has been suggested for
a number of 5-HT6 receptor antagonists in cellular systems
(Romero et al., 2007; Duhr et al., 2014).
Idalopirdine is likely to modulate hippocampal oscillatory ac-
tivity through its effect on cholinergic signaling, as ACh is critical for
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Fig. 7. Plasma and brain concentrations of idalopirdine and donepezil following p.o. and s.c. administration, respectively. Idalopirdine (IDL, 10 mg/kg p.o.) or vehicle (veh)
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K.F. Herrik et al. / Neuropharmacology 107 (2016) 351e363 361theta and gamma oscillations. Indeed, a selective toxin lesion of
septal cholinergic neurons reduced hippocampal theta power (Lee
et al., 1994) whereas in vivo optogenetic activation of these neurons
enhanced theta oscillations in the hippocampus (Vandecasteele
et al., 2014). Cholinergic signaling is also critical for hippocampal
gamma oscillations as these can be induced in hippocampal slice
preparations by cholinergic receptor activation with carbachol or
with the AChEIs physostigmine and donepezil (Fellous and
Sejnowski, 2000; Traub et al., 2000; Spencer et al., 2010;
Pietersen et al., 2014). We therefore postulate that, by enhancing
the effects of donepezil on extracellular ACh levels, idalopirdine
further potentiates the effects of this AChEI on hippocampal oscil-
latory activity. Interestingly however, brain concentrations of ida-
lopirdine required to achieve an effect in nPO model were 2 fold
lower than in the microdialysis paradigm. Although high receptor
occupancy is assumed under both conditions, one possible expla-
nation might be that the electrical stimulation used in the nPO
model mimics an active cholinergic state which is sensitive to 5-
HT6 receptor blockade at lower concentrations of the antagonist
when compared to microdialysis in freely moving rats. In addition,
the observation that higher brain concentrations of idalopirdine are
required to elevate ACh levels in the freelymoving rat, suggests thatampliﬁcation of cholinergic signaling is not the only mechanism
through which idalopirdine potentiates the effects of donepezil on
hippocampal neuronal oscillations. Indeed, idalopirdine is likely to
modulate neuronal oscillations through direct effects on pyramidal
cells and GABAergic interneurons that express the 5-HT6 receptor
(Helboe et al., 2015). Neuronal oscillations reﬂect the summed
synaptic potentials from networks of pyramidal cells and in-
terneurons (Draguhn et al., 2014), although the precise role of the
different types of interneurons remains to be established.We found
5-HT6 receptor mRNA to be expressed by a substantial portion of
hippocampal 5-HT3a receptor- and CB positive and, to a lesser de-
gree, CR positive interneurons (Helboe et al., 2015). It will be of
great interest to study how these individual cell types that express
the 5-HT6 receptor contribute to the effects of idalopirdine on
neuronal oscillations, neurotransmitter levels and ultimately
cognition.
In summary, we show that idalopirdine potentiates the effects of
donepezil on elicited neuronal oscillations and extracellular levels
of ACh in the hippocampus, two neurobiological mechanisms that
are associated with cognitive function. This further supports the
notion that the effects of an AChEI can be augmented by combined
treatment with a 5-HT6 receptor antagonist (Marcos et al., 2008; de
K.F. Herrik et al. / Neuropharmacology 107 (2016) 351e363362Bruin et al., 2011; Dawson, 2011). The ability to increase the ca-
pacity for cholinergic transmission and evoked oscillations in the
hippocampus, a brain region in which aberrant activity is observed
early during the course of the disease, might provide an explana-
tion for the cognitive improvements that are observed when ida-
lopirdine is given as adjunct therapy to donepezil in patients with
AD (Wilkinson et al., 2014).
Acknowledgements
We thank Hossein Armandi and Nina Guldhammer for technical
assistance with the bioanalysis and microdialysis respectively. We
are grateful to Nanna Hovelsø Jensen and Florence Sotty for tech-
nical assistance and fruitful discussions when setting up the elec-
trophysiology assay. In addition, we thank Ross Jeggo and Jan
Egebjerg Jensen for critically proof reading the manuscript.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.neuropharm.2016.03.043.
References
Ahnaou, A., Huysmans, H., Jacobs, T., Drinkenburg, W.H., 2014. Cortical EEG oscil-
lations and network connectivity as efﬁcacy indices for assessing drugs with
cognition enhancing potential. Neuropharmacology 86, 362e377.
Anand, P., Singh, B., 2013. A review on cholinesterase inhibitors for Alzheimer's
disease. Arch. Pharm. Res. 36, 375e399.
Arai, H., Kosaka, K., Iizuka, R., 1984. Changes of biogenic amines and their metab-
olites in postmortem brains from patients with Alzheimer-type dementia.
J. Neurochem. 43, 388e393.
Arnt, J., Bang-Andersen, B., Grayson, B., Bymaster, F.P., Cohen, M.P., DeLapp, N.W.,
et al., 2010. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment
induced by subchronic phencyclidine in a novel object recognition test in rats.
Int. J. Neuropsychopharmacol. 13, 1021e1033.
Babiloni, C., Del, P.C., Bordet, R., Bourriez, J.L., Bentivoglio, M., Payoux, P., et al., 2013.
Effects of acetylcholinesterase inhibitors and memantine on resting-state
electroencephalographic rhythms in Alzheimer's disease patients. Clin. Neuro-
physiol. 124, 837e850.
Basar, E., Basar-Eroglu, C., Guntekin, B., Yener, G.G., 2013. Brain's alpha, beta,
gamma, delta, and theta oscillations in neuropsychiatric diseases: proposal for
biomarker strategies. Suppl. Clin. Neurophysiol. 62, 19e54.
Birks, J., Harvey, R.J., 2006. Donepezil for dementia due to Alzheimer's disease.
Cochrane Database Syst. Rev. CD001190.
Bland, B.H., 1986. The physiology and pharmacology of hippocampal formation
theta rhythms. Prog. Neurobiol. 26, 1e54.
Bland, B.H., Oddie, S.D., 1998. Anatomical, electrophysiological and pharmacological
studies of ascending brainstem hippocampal synchronizing pathways. Neuro-
sci. Biobehav Rev. 22, 259e273.
Buzsaki, G., 2002. Theta oscillations in the hippocampus. Neuron 33, 325e340.
Chuang, A.T.T., Foley, A., Pugh, P.L., Sunter, D., Tong, X., Regan, C., et al., 2006. In: 5-
HT6 Receptor Antagonist SB-742457 as a Novel Cognitive Enhancing Agent for
Alzheimer's Disease, pp. S631eS632.
Colgin, L.L., Denninger, T., Fyhn, M., Hafting, T., Bonnevie, T., Jensen, O., et al., 2009.
Frequency of gamma oscillations routes ﬂow of information in the hippocam-
pus. Nature 462, 353e357.
Cross, A.J., Crow, T.J., Johnson, J.A., Joseph, M.H., Perry, E.K., Perry, R.H., et al., 1983.
Monoamine metabolism in senile dementia of Alzheimer type. J. Neurol. Sci. 60,
383e392.
Davies, P., Maloney, A.J., 1976. Selective loss of central cholinergic neurons in Alz-
heimer's disease. Lancet 2, 1403.
Dawson, L.A., 2011. The central role of 5-HT6 receptors in modulating brain
neurochemistry. Int. Rev. Neurobiol. 96, 1e26.
Dawson, L.A., Nguyen, H.Q., Li, P., 2001. The 5-HT(6) receptor antagonist SB-271046
selectively enhances excitatory neurotransmission in the rat frontal cortex and
hippocampus. Neuropsychopharmacology 25, 662e668.
de Bruin, N.M., Prickaerts, J., van, L.A., Venhorst, J., de, G.L., Houba, P., et al., 2011.
Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced
memory deﬁcits in the object recognition and object location tasks in Wistar
rats. Neurobiol. Learn Mem. 96, 392e402.
Draguhn, A., Keller, M., Reichinnek, S., 2014. Coordinated network activity in the
hippocampus. Front. Neurol. Neurosci. 34, 26e35.
Duhr, F., Deleris, P., Raynaud, F., Seveno, M., Morisset-Lopez, S., Mannoury, C.C.,
et al., 2014. Cdk5 induces constitutive activation of 5-HT6 receptors to promote
neurite growth. Nat. Chem. Biol. 10, 590e597.
East, S.Z., Burnet, P.W., Leslie, R.A., Roberts, J.C., Harrison, P.J., 2002. 5-HT6 receptorbinding sites in schizophrenia and following antipsychotic drug administration:
autoradiographic studies with [125I]SB-258585. Synapse 45, 191e199.
Fellous, J.M., Sejnowski, T.J., 2000. Cholinergic induction of oscillations in the hip-
pocampal slice in the slow (0.5-2 Hz), theta (5-12 Hz), and gamma (35-70 Hz)
bands. Hippocampus 10, 187e197.
Fone, K.C., 2008. An update on the role of the 5-hydroxytryptamine6 receptor in
cognitive function. Neuropharmacology 55, 1015e1022.
Foraster, M.A., Herrik, K.F., Richard, N., Bastlund, J.F., De Jong, I.E., Smagin, G., et al.,
2014. The 5-HT6 receptor antagonist Lu AE58054 alone and in combination
with donepezil potentiates gamma oscillations in rat medial prefrontal cortex.
Alzhheimers Dement. 10, P780eP781.
Helboe, L., Egebjerg, J., De Jong, I.E., 2015. Distribution of serotonin receptor 5-HT6
mRNA in rat neuronal subpopulations: a double in situ hybridization study.
Neuroscience 310, 442e454.
Herrik, K.F., De Jong, I.E., Pedersen, J.T., Helboe, L., Arnt, J., Mørk, A., 2013. The 5-HT6
antagonist Lu AE58054 potentiates the effects of the acetylcholinesterase in-
hibitor donepezil on hippocampal extracellular acetylcholine efﬂux and oscil-
latory activity. Alzhheimers Dement. 9, P503.
Hirst, W.D., Abrahamsen, B., Blaney, F.E., Calver, A.R., Aloj, L., Price, G.W., et al., 2003.
Differences in the central nervous system distribution and pharmacology of the
mouse 5-hydroxytryptamine-6 receptor compared with rat and human re-
ceptors investigated by radioligand binding, site-directed mutagenesis, and
molecular modeling. Mol. Pharmacol. 64, 1295e1308.
Hirst, W.D., Stean, T.O., Rogers, D.C., Sunter, D., Pugh, P., Moss, S.F., et al., 2006. SB-
399885 is a potent, selective 5-HT6 receptor antagonist with cognitive
enhancing properties in aged rat water maze and novel object recognition
models. Eur. J. Pharmacol. 553, 109e119.
Ichimiya, Y., Arai, H., Kosaka, K., Iizuka, R., 1986. Morphological and biochemical
changes in the cholinergic and monoaminergic systems in Alzheimer-type
dementia. Acta Neuropathol. 70, 112e116.
Johnson, D.E., Drummond, E., Grimwood, S., Sawant-Basak, A., Miller, E., Tseng, E.,
et al., 2012. The 5-hydroxytryptamine4 receptor agonists prucalopride and PRX-
03140 increase acetylcholine and histamine levels in the rat prefrontal cortex
and the power of stimulated hippocampal theta oscillations. J. Pharmacol. Exp.
Ther. 341, 681e691.
Jutras, M.J., Fries, P., Buffalo, E.A., 2009. Gamma-band synchronization in the ma-
caque hippocampus and memory formation. J. Neurosci. 29, 12521e12531.
Kinney, G.G., Patino, P., Mermet-Bouvier, Y., Starrett Jr., J.E., Gribkoff, V.K., 1999.
Cognition-enhancing drugs increase stimulated hippocampal theta rhythm
amplitude in the urethane-anesthetized rat. J. Pharmacol. Exp. Ther. 291,
99e106.
Kowalczyk, T., Konopacki, J., 2002. Depth amplitude and phase proﬁles of carbachol-
induced theta in hippocampal formation slices. Brain Res. Bull. 58, 569e574.
Lee, M.G., Chrobak, J.J., Sik, A., Wiley, R.G., Buzsaki, G., 1994. Hippocampal theta
activity following selective lesion of the septal cholinergic system. Neurosci-
ence 62, 1033e1047.
Leiser, S.C., Li, Y., Pehrson, A.L., Dale, E., Smagin, G., Sanchez, C., 2015. Serotonergic
regulation of prefrontal cortical circuitries involved in cognitive processing: a
review of individual 5-HT receptor mechanisms and concerted effects of 5-HT
receptors exempliﬁed by the multimodal antidepressant vortioxetine. ACS
Chem. Neurosci. 6, 970e986.
Ly, S., Pishdari, B., Lok, L.L., Hajos, M., Kocsis, B., 2013. Activation of 5-HT6 receptors
modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem.
Neurosci. 4, 191e199.
Maher-Edwards, G., Dixon, R., Hunter, J., Gold, M., Hopton, G., Jacobs, G., et al., 2011.
SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-
controlled study. Int. J. Geriatr. Psychiatry 26, 536e544.
Marcos, B., Chuang, T.T., Gil-Bea, F.J., Ramirez, M.J., 2008. Effects of 5-HT6 receptor
antagonism and cholinesterase inhibition in models of cognitive impairment in
the rat. Br. J. Pharmacol. 155, 434e440.
Marcos, B., Gil-Bea, F.J., Hirst, W.D., Garcia-Alloza, M., Ramirez, M.J., 2006. Lack of
localization of 5-HT6 receptors on cholinergic neurons: implication of multiple
neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release.
Eur. J. Neurosci. 24, 1299e1306.
McNaughton, N., Kocsis, B., Hajos, M., 2007. Elicited hippocampal theta rhythm: a
screen for anxiolytic and procognitive drugs through changes in hippocampal
function? Behav. Pharmacol. 18, 329e346.
Meneses, A., 2013. 5-HT systems: emergent targets for memory formation and
memory alterations. Rev. Neurosci. 24, 629e664.
Meneses, A., Perez-Garcia, G., Ponce-Lopez, T., Castillo, C., 2011. 5-HT6 receptor
memory and amnesia: behavioral pharmacologyelearning and memory pro-
cesses. Int. Rev. Neurobiol. 96, 27e47.
Mitchell, E.S., Neumaier, J.F., 2005. 5-HT6 receptors: a novel target for cognitive
enhancement. Pharmacol. Ther. 108, 320e333.
Monsma Jr., F.J., Shen, Y., Ward, R.P., Hamblin, M.W., Sibley, D.R., 1993. Cloning and
expression of a novel serotonin receptor with high afﬁnity for tricyclic psy-
chotropic drugs. Mol. Pharmacol. 43, 320e327.
Nyhus, E., Curran, T., 2010. Functional role of gamma and theta oscillations in
episodic memory. Neurosci. Biobehav Rev. 34, 1023e1035.
Parker, C.A., Gunn, R.N., Rabiner, E.A., Slifstein, M., Comley, R., Salinas, C., et al., 2012.
Radiosynthesis and characterization of 11C-GSK215083 as a PET radioligand for
the 5-HT6 receptor. J. Nucl. Med. 53, 295e303.
Paxinos, G., Watson, C., 1986. The Rat Brain in Stereotaxic Coordinates. Academic
Press.
Pietersen, A.N., Ward, P.D., Hagger-Vaughan, N., Wiggins, J., Jefferys, J.G.,
K.F. Herrik et al. / Neuropharmacology 107 (2016) 351e363 363Vreugdenhil, M., 2014. Transition between fast and slow gamma modes in rat
hippocampus area CA1 in vitro is modulated by slow CA3 gamma oscillations.
J. Physiol. 592, 605e620.
Raina, P., Santaguida, P., Ismaila, A., Patterson, C., Cowan, D., Levine, M., et al., 2008.
Effectiveness of cholinesterase inhibitors and memantine for treating demen-
tia: evidence review for a clinical practice guideline. Ann. Intern Med. 148,
379e397.
Ramirez, M.J., 2013. 5-HT6 receptors and Alzheimer's disease. Alzheimers Res. Ther.
5, 15.
Riemer, C., Borroni, E., Levet-Traﬁt, B., Martin, J.R., Poli, S., Porter, R.H., et al., 2003.
Inﬂuence of the 5-HT6 receptor on acetylcholine release in the cortex: phar-
macological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-
sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist.
J. Med. Chem. 46, 1273e1276.
Roberts, J.C., Reavill, C., East, S.Z., Harrison, P.J., Patel, S., Routledge, C., et al., 2002.
The distribution of 5-HT(6) receptors in rat brain: an autoradiographic binding
study using the radiolabelled 5-HT(6) receptor antagonist [(125)I]SB-258585.
Brain Res. 934, 49e57.
Rogers, S.L., Cooper, N.M., Sukovaty, R., Pederson, J.E., Lee, J.N., Friedhoff, L.T., 1998.
Pharmacokinetic and pharmacodynamic proﬁle of donepezil HCl following
multiple oral doses. Br. J. Clin. Pharmacol. 1 (46), 7e12.
Romero, G., Pujol, M., Perez, P., Buschmann, H., Pauwels, P.J., 2007. Whole spectrum
analysis of ligand efﬁcacy at constitutively active human wild-type and S267K
5-HT6 receptors in HEK-293F cells. J. Pharmacol. Toxicol. Methods 55, 144e150.
Ruat, M., Traiffort, E., Arrang, J.M., Tardivel-Lacombe, J., Diaz, J., Leurs, R., et al., 1993.
A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and
stimulation of cAMP accumulation. Biochem. Biophys. Res. Commun. 193,
268e276.
Schechter, L.E., Lin, Q., Smith, D.L., Zhang, G., Shan, Q., Platt, B., et al., 2008.
Neuropharmacological proﬁle of novel and selective 5-HT6 receptor agonists:
WAY-181187 and WAY-208466. Neuropsychopharmacology 33, 1323e1335.
Siok, C.J., Cogan, S.M., Shifﬂett, L.B., Doran, A.C., Kocsis, B., Hajos, M., 2012.
Comparative analysis of the neurophysiological proﬁle of group II metabotropic
glutamate receptor activators and diazepam: effects on hippocampal and
cortical EEG patterns in rats. Neuropharmacology 62, 226e236.
Siok, C.J., Taylor, C.P., Hajos, M., 2009. Anxiolytic proﬁle of pregabalin on elicited
hippocampal theta oscillation. Neuropharmacology 56, 379e385.
Sorman, E., Wang, D., Hajos, M., Kocsis, B., 2011. Control of hippocampal theta
rhythm by serotonin: role of 5-HT2c receptors. Neuropharmacology 61,
489e494.Spencer, J.P., Middleton, L.J., Davies, C.H., 2010. Investigation into the efﬁcacy of the
acetylcholinesterase inhibitor, donepezil, and novel procognitive agents to
induce gamma oscillations in rat hippocampal slices. Neuropharmacology 59,
437e443.
Stoiljkovic, M., Kelley, C., Nagy, D., Hajos, M., 2015. Modulation of hippocampal
neuronal network oscillations by alpha7 nACh receptors. Biochem. Pharmacol.
97, 445e453.
Tan, C.C., Yu, J.T., Wang, H.F., Tan, M.S., Meng, X.F., Wang, C., et al., 2014. Efﬁcacy and
safety of donepezil, galantamine, rivastigmine, and memantine for the treat-
ment of Alzheimer's disease: a systematic review and meta-analysis.
J. Alzheimers Dis. 41, 615e631.
Tiseo, P.J., Rogers, S.L., Friedhoff, L.T., 1998. Pharmacokinetic and pharmacodynamic
proﬁle of donepezil HCl following evening administration. Br. J. Clin. Pharmacol.
1 (46), 13e18.
Traub, R.D., Bibbig, A., Fisahn, A., LeBeau, F.E., Whittington, M.A., Buhl, E.H., 2000.
A model of gamma-frequency network oscillations induced in the rat CA3 re-
gion by carbachol in vitro. Eur. J. Neurosci. 12, 4093e4106.
Tsuno, N., 2009. Donepezil in the treatment of patients with Alzheimer's disease.
Expert Rev. Neurother. 9, 591e598.
Vandecasteele, M., Varga, V., Berenyi, A., Papp, E., Bartho, P., Venance, L., et al., 2014.
Optogenetic activation of septal cholinergic neurons suppresses sharp wave
ripples and enhances theta oscillations in the hippocampus. Proc. Natl. Acad.
Sci. U. S. A. 111, 13535e13540.
Vertes, R.P., 1981. An analysis of ascending brain stem systems involved in hippo-
campal synchronization and desynchronization. J. Neurophysiol. 46, 1140e1159.
Vertes, R.P., 1982. Brain stem generation of the hippocampal EEG. Prog. Neurobiol.
19, 159e186.
Vertes, R.P., 2005. Hippocampal theta rhythm: a tag for short-term memory. Hip-
pocampus 15, 923e935.
Whitehouse, P.J., Price, D.L., Struble, R.G., Clark, A.W., Coyle, J.T., Delon, M.R., 1982.
Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain.
Science 215, 1237e1239.
Wilkinson, D., Windfeld, K., Colding-Jorgensen, E., 2014. Safety and efﬁcacy of
idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alz-
heimer's disease (LADDER): a randomised, double-blind, placebo-controlled
phase 2 trial. Lancet Neurol. 13, 1092e1099.
Zhu, X.O., McNaughton, N., 1994. The interaction of serotonin depletion with an-
xiolytics and antidepressants on reticular-elicited hippocampal RSA. Neuro-
pharmacology 33, 1597e1605.
